The Food and Drug Administration (FDA) has approved the first generics of Eliquis (apixaban; Bristol-Myers Squibb and Pfizer) tablets. Apixaban, a factor Xa inhibitor, is indicated: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism…
Your search for apixaban returned 85 results
Findings seen among older patients with incident atrial fibrillation receiving warfarin or apixaban
Less knowledge about OTC products with potentially serious interactions linked to increased use
According to the findings of a recent study, attorney advertisements appear to influence patients’ decisions on modifying or discontinuing their direct oral anticoagulant (DOAC) medication prior to seeking medical advice.
Results from the phase 4 AUGUSTUS trial, evaluating apixaban vs vitamin K antagonists in patients with nonvalvular atrial fibrillation and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention.
Bolus plus two-hour infusion of andexanet alfa cuts antifactor Xa activity by 92 percent
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban vs placebo.
To compare the incidence of hospitalization for upper GI tract bleeding, researchers used US Medicare beneficiary files to identify a cohort of patients that were ≥30 years old who initiated oral anticoagulation therapy with apixaban, dabigatran, rivaroxaban, or warfarin, with or without PPI cotherapy.